Stock Under $10 with 50-100% upside potential - 14 Days FREE!

Drugs

Quick Take: The Next Big Thing in Biotech

TheStreet's senior columnist Adam Feuerstein and Gregg Greenberg discuss winners and losers from research abstracts ahead of the ASCO cancer conference.

05/17/13 - 10:44 AM EDT

The 5 Dumbest Things on Wall Street This Week: May 17

Dan Loeb gets soft, Bloomberg and traders are 'Spy vs. Spy,' and Wal-Mart torpedos a cooperative reform effort by choosing its own, awkward path.

05/17/13 - 07:00 AM EDT

Try Jim Cramer's Action Alerts PLUS
Morning Briefing: 10 Things You Should Know

Morning Briefing: 10 Things You Should Know

Stock futures are flat; Cisco's earnings and revenue top forecasts; Wal-Mart's profit misses Wall Street estimates; Novartis eyes Actavis.

05/16/13 - 07:33 AM EDT

10 ASCO '13 Abstracts You Can Read Right Now

10 ASCO '13 Abstracts You Can Read Right Now

Get a head start on searching through ASCO abstracts with these 10 summaries.

05/15/13 - 06:00 PM EDT

Aveo Screwed Up but Its Kidney Cancer Drug Is Real

Aveo Screwed Up but Its Kidney Cancer Drug Is Real

At some point, investors will give Aveo credit for tivozanib, says David Sobek.

05/15/13 - 09:24 AM EDT

Synta Is Run-Up to ASCO Lung Cancer Data

Synta Is Run-Up to ASCO Lung Cancer Data

  • Tickers in this article:
  • SNTA
  • HSP

The market overreacted to the resignation of Synta's R&D chief.

05/14/13 - 10:16 AM EDT

TheStreet Ratings Top 10 Rating Changes

TheStreet Ratings Top 10 Rating Changes

TheStreet Ratings released rating changes on 77 U.S. common stocks for week ending May 13, 2013. 45 stocks were upgraded and 32 stocks were downgraded by our stock model.

05/13/13 - 01:21 PM EDT

Video
Quintiles IPO Trades Higher Quintiles IPO Trades Higher
  • Tickers in this article:
  • Q
  • NYX

Quintiles Transnational prices its IPo at the high end of the range and moves higher in trading. CEO Tom Pike sees more growth ahead.

05/13/13 - 10:47 AM EDT

Morning Briefing: 10 Things You Should Know

Morning Briefing: 10 Things You Should Know

U.S. stock futures point lower ahead of a retail sales report; Elan and Theravance in a $1 billion royalty agreement; Post Holdings and Take-Two report earnings.

05/13/13 - 07:27 AM EDT

SEC Is Investigating Spectrum Pharma

SEC Is Investigating Spectrum Pharma

  • Tickers in this article:
  • SPPI

Regulators have issued a subpoena to Spectrum for information related to the steep cut in Fusilev sales in 2013.

05/13/13 - 07:19 AM EDT

The Deal: Bain, TPG Get Windfall With Quintiles IPO

The Deal: Bain, TPG Get Windfall With Quintiles IPO

  • Tickers in this article:
  • Q

Quintiles raises $947 million for investors including Bain and TPG Group as the research services company goes public.

05/10/13 - 11:51 AM EDT

Repros Patent Problems Began When Harry Met Joe

Repros Patent Problems Began When Harry Met Joe

  • Tickers in this article:
  • RPRX

A New York fertility doctor accuses Repros CEO of stealing the idea for a new oral testosterone therapy.

05/09/13 - 08:00 AM EDT

Happy Day for Arena Bulls, Bears as Belviq Launch Finally Arrives

Happy Day for Arena Bulls, Bears as Belviq Launch Finally Arrives

DEA finalizes Belviq abuse schedule, allowing the weight-loss pill launch in June.

05/07/13 - 11:53 AM EDT

Fire Aveo's CEO for Incompetence and Arrogance Rivaling ImClone's Sam Waksal

Fire Aveo's CEO for Incompetence and Arrogance Rivaling ImClone's Sam Waksal

  • Tickers in this article:
  • AVEO

Heads need to roll at Aveo because of the FDA's thrashing of the company's kidney cancer drug.

05/06/13 - 12:26 PM EDT

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 15,354.40 121.18 0.80%
NASDAQ 3,498.97 33.73 0.97%
S&P 500 1,667.47 17.00 1.03%
US 10 Yr 1.949% +0.084

Brokerage Partners

Advertising Partners

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy.

Top Rated Stocks Top Rated Funds Top Rated ETFs